Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Protagonist Therapeutics IncPTGX | $90.25 | Strong Buy | $115.00 | +27.42% | 2 days ago | |
Analyst RankingTop 11% #568 out of 5136 analysts Average Return+7.36% Win Rate56%98 out of 175 Risk vs RewardPoor Good Analyst ColorCitigroup's Geoff Meacham raised their price target on Protagonist Therapeutics (NASDAQ: PTGX) by 17.3% from $98 to $115 on 2025/12/08. The analyst maintained their Strong Buy rating on the stock. Protagonist Therapeutics' Japan-based partner, Takeda Pharmaceutical, announced positive Phase 3 VERIFY data highlighting the durability of rusfertide, Meacham reported. Citigroup now sees peak rusfertide worldwide sales in 2032 of $3B, the analyst detailed. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.